CIMA LABS INC. Patent applications |
Patent application number | Title | Published |
20130266660 | ALCOHOL-RESISTANT METOPROLOL-CONTAINING EXTENDED-RELEASE ORAL DOSAGE FORMS - This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing metoprolol or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance. | 10-10-2013 |
20130209560 | ABUSE-RESISTANT FORMULATIONS - This disclosure relates to a sustained-release oral dosage form suitable for twice-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydrocodone. The dosage form can have a release profile such that 6 hours following administration, less than about 80 percent of the hydrocodone is released. In addition, the dosage form may have alcohol and/or crush resistance. | 08-15-2013 |
20130202705 | ALCOHOL-RESISTANT FORMULATIONS - This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing a high water-soluble, high dose drug. The dosage form has alcohol resistance and may also have crush resistance. | 08-08-2013 |
20130171256 | ALCOHOL-RESISTANT EXTENDED RELEASE DOSAGE FORMS COMPRISING VENLAFAXINE - This disclosure relates to an extended release oral dosage form comprising a matrix containing a viscosity modifier (but no lipid) and coated granules containing venlafaxine or a pharmaceutically acceptable salt or solvate thereof. The dosage form has alcohol resistance and may also have crush resistance. | 07-04-2013 |
20120225122 | Abuse-Resistant Formulations - This disclosure relates to a sustained-release oral dosage form for once-a-day administration comprising a matrix containing a viscosity modifier and coated granules containing hydromorphone. The dosage form can have a release profile such that 16 hours following administration, less than about 85 percent of the hydromorphone is released. In addition, the dosage form may have alcohol and/or crush resistance. | 09-06-2012 |
20120213855 | DOSAGE FORMS FOR WEAKLY IONIZABLE COMPOUNDS - This disclosure relates to dosage forms (e.g., solid dosage forms) comprising a drug-containing emulsion, a drug-containing microemulsion, a self-emulsifying oil composition, or a self-microemulsifying oil composition, wherein each comprises a weakly ionizable drug and a pH modifier. Also provided are pharmaceutical dosage forms (e.g., solid dosage forms) and methods of preparing the same. | 08-23-2012 |
20110223115 | SUBLINGUAL BUCCAL EFFERVESCENT - A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed. | 09-15-2011 |
20110212034 | Sublingual Buccal Effervescent - A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administrable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of an additional pH adjusting substance in combination with the effervescent for promoting the absorption drugs is also disclosed. | 09-01-2011 |
20110206621 | ORAL TRANSMUCOSAL NICOTINE DOSAGE FORM - The invention described herein relates to an oral transmucosal solid dosage form useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the invention transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size. | 08-25-2011 |
20110073518 | Generally Linear Effervescent Oral Fentanyl Dosage Form and Methods of Administering - Fentanyl containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than know oral formulation and have advantages in terms of cost and side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa. | 03-31-2011 |
20110071181 | EFFERVESCENT ORAL OPIATE DOSAGE FORMS AND METHODS OF ADMINISTERING OPIATES - Opiate containing dosage forms and methods using same are described. These dosage forms include substantially less opiates by weight than known oral formulations. These dosage forms are intended for oral administration across the oral mucosa. | 03-24-2011 |
20110070169 | Effervescent Oral Fentanyl Dosage Form and Methods of Administering Fentanyl - Fentanyl-containing dosage forms and methods using same are described. These dosage forms include substantially less fentanyl by weight than known oral formulation and have advantages in terms of reduced cost and reduced side effects. These dosage forms are intended for oral administration of fentanyl across the oral mucosa. | 03-24-2011 |
20090214442 | Oral Transmucosal Nicotine Dosage Form - Described herein are oral transmucosal solid dosage forms useful in treating nicotine addiction or as a nicotine substitute or replacement. By virtue of the formulation in combination with nicotine, the dosage forms transmucosally delivers an effective amount of nicotine to the recipient while permitting the accomplishing of such, and manufacture of such, using a relatively small, convenient and orally comfortable dosage form (e.g., tablet) size. | 08-27-2009 |
20090202632 | Sublingual Buccal Effervescent - A pharmaceutical dosage form adapted to supply a medicament to the oral cavity for buccal, sublingual or gingival absorption of the medicament which contains an orally administerable medicament in combination with an effervescent for use in promoting absorption of the medicament in the oral cavity. The use of additional pH adjusting substance in combination with the effervescent for promoting the absorption of drugs is also disclosed. | 08-13-2009 |